2007至2017年韩国H9N2低致病性禽流感商品疫苗的销售与免疫原性
本研究监测2007至2017年韩国生产的H9N2商品疫苗的销售与免疫原性。多价联合疫苗约占全部疫苗销量的90%,约30%的疫苗由地方政府免费分发。自2009年以来无田间感染病例。研究期间平均抗体滴度为5.82 log2。
要点
- 多价联合疫苗占销量约90%,约30%疫苗由地方政府免费分发。
- 自2009年以来无田间感染病例,研究期间平均抗体滴度5.82 log2。
核心结论
- 作者认为,为控制H9N2暴发,需持续对田间流行的H9N2病毒进行遗传监测并定期更新疫苗种子株。
研究设计与样本
- 本研究监测2007至2017年韩国生产的H9N2商品疫苗的销售活动与免疫原性。
主要发现
- 多价联合疫苗约占全部疫苗销量的90%,约30%的疫苗由地方政府免费分发。
- 地区接种率以京畿道和忠清南道最高,分别与蛋鸡和种鸡的种群数量成比例。
- 自2009年以来无田间感染病例。
- 研究期间平均抗体滴度为5.82 log2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study was conducted to monitor sales activity and immunogenicity of commercial H9N2 vaccines produced in Korea from 2007 to 2017. Recorded sales of H9N2 vaccine were around 671 million doses, with 10 million doses sold in 2007, rising to a peak of 93 million doses in 2016, with a slight fall in 2017. Multivalent combined vaccines made up around 90% of all vaccine sales, and around 30% of all vaccines were distributed by regional governments for free. The regional vaccination rate was the highest in Gyeonggi and Chungnam, respectively with proportional to the population of layer and breeder chickens. There have been no cases of field infection since 2009. The mean antibody titer was 5.82 log2 across the study period. Our results suggest that continuous genetic monitoring of H9N2 viruses circulating in the field and updating the vaccine seed strain periodically are necessary in order to control H9N2 outbreaks.
引用
- Cho HK, Kang YM, Kim HM, et al. Sales and immunogenicity of commercial vaccines to H9N2 low pathogenic avian influenza virus in Korea from 2007 to 2017. Vaccine. 2020. PMID: 32169392. doi:10.1016/j.vaccine.2020.02.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。